InspireMD (NSPR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

NSPR Stock Forecast

InspireMD stock forecast is as follows: an average price target of $4.50 (represents a 75.10% upside from NSPR’s last price of $2.57) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

NSPR Price Target

The average price target for InspireMD (NSPR) is $4.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $4.50 to $4.50. This represents a potential 75.10% upside from NSPR's last price of $2.57.

NSPR Analyst Ratings

Buy

According to 1 Wall Street analysts, InspireMD's rating consensus is 'Buy'. The analyst rating breakdown for NSPR stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

InspireMD Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 17, 2024	Adam Maeder	Piper Sandler	$4.50	$2.61	72.41%	75.10%

Row per page

Go to

The latest InspireMD stock forecast, released on Sep 17, 2024 by Adam Maeder from Piper Sandler, set a price target of $4.50, which represents a 72.41% increase from the stock price at the time of the forecast ($2.61), and a 75.10% increase from NSPR last price ($2.57).

InspireMD Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$4.50	$4.50
Last Closing Price	$2.57	$2.57	$2.57
Upside/Downside	-100.00%	75.10%	75.10%

In the current month, the average price target of InspireMD stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to InspireMD's last price of $2.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 17, 2024	Piper Sandler	Overweight	Overweight	Hold

Row per page

Go to

InspireMD's last stock rating was published by Piper Sandler on Sep 17, 2024. The company gave NSPR a "Overweight" rating, the same as its previous rate.

InspireMD Financial Forecast

InspireMD Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 16	Mar 15
Revenue	-	-	-	-	-	-	-	-	$1.76M	$1.56M	$1.65M	$1.24M	$1.03M	$1.43M	$1.53M	$1.18M	$1.38M	$1.07M	$1.04M	$1.01M	$158.00K	$980.00K	$313.00K	$1.03M	$1.01M	$939.00K	$1.35M	$415.00K	$563.00K	$477.00K
Avg Forecast	$3.32M	$2.83M	$2.51M	$1.88M	$1.83M	$1.74M	$1.74M	$2.00M	$1.63M	$1.50M	$1.55M	$1.00M	$1.00M	$1.40M	$1.20M	$1.40M	$1.30M	$1.20M	$1.10M	$900.00K	$1.20M	$600.00K	$200.00K	$1.00M	$1.60M	$1.40M	$1.30M	$1.10M	$612.50K	$240.00K
High Forecast	$3.32M	$2.83M	$2.51M	$1.88M	$1.83M	$1.74M	$1.74M	$2.00M	$1.63M	$1.50M	$1.55M	$1.00M	$1.00M	$1.40M	$1.20M	$1.40M	$1.30M	$1.20M	$1.10M	$900.00K	$1.20M	$600.00K	$200.00K	$1.00M	$1.60M	$1.40M	$1.30M	$1.10M	$735.00K	$288.00K
Low Forecast	$3.32M	$2.83M	$2.51M	$1.88M	$1.83M	$1.74M	$1.74M	$2.00M	$1.63M	$1.50M	$1.55M	$1.00M	$1.00M	$1.40M	$1.20M	$1.40M	$1.30M	$1.20M	$1.10M	$900.00K	$1.20M	$600.00K	$200.00K	$1.00M	$1.60M	$1.40M	$1.30M	$1.10M	$490.00K	$192.00K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4	3	4	3	8	10
Surprise %	-	-	-	-	-	-	-	-	1.08%	1.04%	1.07%	1.24%	1.03%	1.02%	1.28%	0.84%	1.06%	0.89%	0.94%	1.12%	0.13%	1.63%	1.56%	1.03%	0.63%	0.67%	1.04%	0.38%	0.92%	1.99%

InspireMD's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.00M, with a low forecast of $2.00M, and a high forecast of $2.00M. NSPR's average Quarter revenue forecast represents a 13.57% increase compared to the company's last Quarter revenue of $1.76M (Dec 23).

InspireMD EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 16	Mar 15
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4	3	4	3	8	10
EBITDA	-	-	-	-	-	-	-	-	$15.81M	$-5.64M	$-5.32M	$-4.33M	$-4.94M	$-4.56M	$-4.68M	$-4.45M	$-3.89M	$-3.99M	$-3.41M	$-3.19M	$-3.69M	$-2.16M	$-2.44M	$-1.93M	$-2.49M	$-2.03M	$-2.17M	$-3.17M	$-2.38M	$-4.82M
Avg Forecast	$-3.32M	$-2.83M	$-2.51M	$-1.88M	$-1.83M	$-1.74M	$-1.74M	$-2.00M	$-1.63M	$-1.50M	$-1.55M	$-1.00M	$-1.00M	$-1.40M	$-1.20M	$-5.71M	$-1.30M	$-1.20M	$-1.10M	$-3.56M	$-1.20M	$-600.00K	$-200.00K	$-2.54M	$-1.60M	$-1.40M	$-1.30M	$-1.65M	$-2.59M	$-5.30M
High Forecast	$-3.32M	$-2.83M	$-2.51M	$-1.88M	$-1.83M	$-1.74M	$-1.74M	$-2.00M	$-1.63M	$-1.50M	$-1.55M	$-1.00M	$-1.00M	$-1.40M	$-1.20M	$-4.57M	$-1.30M	$-1.20M	$-1.10M	$-2.85M	$-1.20M	$-600.00K	$-200.00K	$-2.03M	$-1.60M	$-1.40M	$-1.30M	$-1.32M	$-2.07M	$-4.24M
Low Forecast	$-3.32M	$-2.83M	$-2.51M	$-1.88M	$-1.83M	$-1.74M	$-1.74M	$-2.00M	$-1.63M	$-1.50M	$-1.55M	$-1.00M	$-1.00M	$-1.40M	$-1.20M	$-6.85M	$-1.30M	$-1.20M	$-1.10M	$-4.28M	$-1.20M	$-600.00K	$-200.00K	$-3.05M	$-1.60M	$-1.40M	$-1.30M	$-1.98M	$-3.10M	$-6.36M
Surprise %	-	-	-	-	-	-	-	-	-9.73%	3.76%	3.44%	4.33%	4.94%	3.26%	3.90%	0.78%	2.99%	3.33%	3.10%	0.90%	3.07%	3.60%	12.21%	0.76%	1.56%	1.45%	1.67%	1.93%	0.92%	0.91%

1 analysts predict NSPR's average Quarter EBITDA for Mar 24 to be $-2.00M, with a high of $-2.00M and a low of $-2.00M. This is -112.65% lower than InspireMD's previous annual EBITDA (Dec 23) of $15.81M.

InspireMD Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 16	Mar 15
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4	3	4	3	8	10
Net Income	-	-	-	-	-	-	-	-	$15.68M	$461.00K	$-5.08M	$-4.13M	$-4.84M	$-4.45M	$-4.59M	$-4.48M	$-4.10M	$-4.11M	$-3.57M	$-3.17M	$-3.85M	$-2.27M	$-2.51M	$-1.94M	$-2.56M	$-2.14M	$-2.23M	$-3.28M	$-2.61M	$-5.21M
Avg Forecast	$-9.67M	$-10.16M	$-8.71M	$-6.77M	$-9.67M	$-9.67M	$-9.19M	$-8.71M	$-9.19M	$-6.77M	$-20.80M	$-32.89M	$-40.63M	$-26.19M	$-26.19M	$-5.77M	$-27.98M	$-29.42M	$-22.60M	$-3.62M	$-32.29M	$-43.05M	$-188.36M	$-2.61M	$-306.76M	$-726.53M	$-1.08B	$-1.67M	$-2.83M	$-5.73M
High Forecast	$-9.67M	$-10.16M	$-8.71M	$-6.77M	$-9.67M	$-9.67M	$-9.19M	$-8.71M	$-9.19M	$-6.77M	$-20.80M	$-32.89M	$-40.63M	$-26.19M	$-26.19M	$-4.62M	$-27.98M	$-29.42M	$-22.60M	$-2.90M	$-32.29M	$-43.05M	$-188.36M	$-2.08M	$-306.76M	$-726.53M	$-1.08B	$-1.33M	$-2.27M	$-4.59M
Low Forecast	$-9.67M	$-10.16M	$-8.71M	$-6.77M	$-9.67M	$-9.67M	$-9.19M	$-8.71M	$-9.19M	$-6.77M	$-20.80M	$-32.89M	$-40.63M	$-26.19M	$-26.19M	$-6.92M	$-27.98M	$-29.42M	$-22.60M	$-4.35M	$-32.29M	$-43.05M	$-188.36M	$-3.13M	$-306.76M	$-726.53M	$-1.08B	$-2.00M	$-3.40M	$-6.88M
Surprise %	-	-	-	-	-	-	-	-	-1.71%	-0.07%	0.24%	0.13%	0.12%	0.17%	0.18%	0.78%	0.15%	0.14%	0.16%	0.88%	0.12%	0.05%	0.01%	0.74%	0.01%	0.00%	0.00%	1.97%	0.92%	0.91%

InspireMD's average Quarter net income forecast for Mar 24 is $-8.71M, with a range of $-8.71M to $-8.71M. NSPR's average Quarter net income forecast represents a -155.53% decrease compared to the company's last Quarter net income of $15.68M (Dec 23).

InspireMD SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 16	Mar 15
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4	3	4	3	8	10
SG&A	-	-	-	-	-	-	-	-	$4.28M	$3.97M	$3.81M	$2.91M	$3.12M	$2.92M	$3.06M	$2.93M	$2.69M	$2.63M	$2.41M	$2.58M	$2.61M	$1.95M	$1.88M	$1.79M	$2.24M	$1.68M	$1.76M	$1.93M	$1.98M	$2.99M
Avg Forecast	$8.24M	$7.02M	$6.21M	$4.65M	$4.54M	$4.32M	$4.30M	$4.96M	$4.03M	$3.71M	$3.83M	$2.48M	$2.48M	$3.46M	$2.96M	$3.46M	$3.21M	$2.96M	$2.72M	$2.22M	$2.96M	$1.48M	$493.96K	$2.47M	$3.95M	$3.46M	$3.21M	$1.00M	$1.51M	$592.75K
High Forecast	$8.24M	$7.02M	$6.21M	$4.65M	$4.54M	$4.32M	$4.30M	$4.96M	$4.03M	$3.71M	$3.83M	$2.48M	$2.48M	$3.46M	$2.96M	$3.46M	$3.21M	$2.96M	$2.72M	$2.22M	$2.96M	$1.48M	$493.96K	$2.47M	$3.95M	$3.46M	$3.21M	$1.20M	$1.82M	$711.30K
Low Forecast	$8.24M	$7.02M	$6.21M	$4.65M	$4.54M	$4.32M	$4.30M	$4.96M	$4.03M	$3.71M	$3.83M	$2.48M	$2.48M	$3.46M	$2.96M	$3.46M	$3.21M	$2.96M	$2.72M	$2.22M	$2.96M	$1.48M	$493.96K	$2.47M	$3.95M	$3.46M	$3.21M	$802.48K	$1.21M	$474.20K
Surprise %	-	-	-	-	-	-	-	-	1.06%	1.07%	1.00%	1.17%	1.26%	0.84%	1.03%	0.85%	0.84%	0.89%	0.89%	1.16%	0.88%	1.31%	3.81%	0.73%	0.57%	0.49%	0.55%	1.93%	1.31%	5.04%

InspireMD's average Quarter SG&A projection for Mar 24 is $4.96M, based on 1 Wall Street analysts, with a range of $4.96M to $4.96M. The forecast indicates a 15.85% rise compared to NSPR last annual SG&A of $4.28M (Dec 23).

InspireMD EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 16	Mar 15
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	4	3	4	3	8	10
EPS	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.51	$-0.60	$-0.57	$-0.59	$-0.57	$-0.53	$-0.53	$-0.46	$-0.52	$-1.52	$-0.98	$-2.97	$-6.28	$-8.62	$-19.50	$-24.17	$-58.68	$-163.06K	$-473.82K
Avg Forecast	$-0.20	$-0.21	$-0.18	$-0.14	$-0.20	$-0.20	$-0.19	$-0.18	$-0.19	$-0.14	$-0.43	$-0.68	$-0.84	$-0.73	$-0.73	$-0.80	$-0.78	$-0.82	$-0.63	$-0.60	$-0.90	$-1.20	$-5.25	$-9.45	$-8.55	$-20.25	$-30.00	$-37.50	$-9.50	$-13.75
High Forecast	$-0.20	$-0.21	$-0.18	$-0.14	$-0.20	$-0.20	$-0.19	$-0.18	$-0.19	$-0.14	$-0.43	$-0.68	$-0.84	$-0.73	$-0.73	$-0.80	$-0.78	$-0.82	$-0.63	$-0.60	$-0.90	$-1.20	$-5.25	$-9.45	$-8.55	$-20.25	$-30.00	$-37.50	$-7.60	$-11.00
Low Forecast	$-0.20	$-0.21	$-0.18	$-0.14	$-0.20	$-0.20	$-0.19	$-0.18	$-0.19	$-0.14	$-0.43	$-0.68	$-0.84	$-0.73	$-0.73	$-0.80	$-0.78	$-0.82	$-0.63	$-0.60	$-0.90	$-1.20	$-5.25	$-9.45	$-8.55	$-20.25	$-30.00	$-37.50	$-11.40	$-16.50
Surprise %	-	-	-	-	-	-	-	-	-0.00%	-	0.00%	0.75%	0.71%	0.78%	0.81%	0.71%	0.68%	0.65%	0.73%	0.87%	1.69%	0.82%	0.57%	0.66%	1.01%	0.96%	0.81%	1.56%	17164.47%	34459.50%

According to 1 Wall Street analysts, InspireMD's projected average Quarter EPS for Mar 24 is $-0.18, with a low estimate of $-0.18 and a high estimate of $-0.18. This represents a -30100.00% decrease compared to NSPR previous annual EPS of - (Dec 23).

InspireMD Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VAPO	Vapotherm	$2.17	$128.00	5798.62%	Hold
RPID	Rapid Micro Biosystems	$1.10	$8.00	627.27%	Hold
AZYO	Elutia	$1.49	$10.25	587.92%	Buy
BJDX	Bluejay Diagnostics	$3.24	$10.00	208.64%	Buy
SGHT	Sight Sciences	$3.77	$9.00	138.73%	Hold
NSPR	InspireMD	$2.57	$4.50	75.10%	Buy
NPCE	NeuroPace	$9.18	$12.88	40.31%	Buy
SRDX	Surmodics	$39.19	$39.50	0.79%	Buy

NSPR Forecast FAQ

Is InspireMD a good buy?

Yes, according to 1 Wall Street analysts, InspireMD (NSPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of NSPR's total ratings.

What is NSPR's price target?

InspireMD (NSPR) average price target is $4.5 with a range of $4.5 to $4.5, implying a 75.10% from its last price of $2.57. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will InspireMD stock go up soon?

According to Wall Street analysts' prediction for NSPR stock, the company can go up by 75.10% (from the last price of $2.57 to the average price target of $4.5), up by 75.10% based on the highest stock price target, and up by 75.10% based on the lowest stock price target.

Can InspireMD stock reach $4?

NSPR's average twelve months analyst stock price target of $4.5 supports the claim that InspireMD can reach $4 in the near future.

What are InspireMD's analysts' financial forecasts?

InspireMD's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $7.31M (high $7.31M, low $7.31M), average EBITDA is $-7.312M (high $-7.312M, low $-7.312M), average net income is $-37.244M (high $-37.244M, low $-37.244M), average SG&A $18.12M (high $18.12M, low $18.12M), and average EPS is $-0.77 (high $-0.77, low $-0.77). NSPR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $10.54M (high $10.54M, low $10.54M), average EBITDA is $-10.541M (high $-10.541M, low $-10.541M), average net income is $-35.31M (high $-35.31M, low $-35.31M), average SG&A $26.12M (high $26.12M, low $26.12M), and average EPS is $-0.73 (high $-0.73, low $-0.73).

Did the NSPR's actual financial results beat the analysts' financial forecasts?

Based on InspireMD's last annual report (Dec 2023), the company's revenue was $6.2M, beating the average analysts forecast of $5.67M by 9.45%. Apple's EBITDA was $-21.143M, beating the average prediction of $-5.67M by 272.93%. The company's net income was $1.29M, missing the average estimation of $-69.652M by -101.85%. Apple's SG&A was $14.97M, beating the average forecast of $14.05M by 6.55%. Lastly, the company's EPS was $0.0001, missing the average prediction of $-1.44 by -100.01%. In terms of the last quarterly report (Dec 2023), InspireMD's revenue was $1.76M, beating the average analysts' forecast of $1.63M by 8.34%. The company's EBITDA was $15.82M, missing the average prediction of $-1.626M by -1072.93%. InspireMD's net income was $15.68M, missing the average estimation of $-9.19M by -270.59%. The company's SG&A was $4.28M, beating the average forecast of $4.03M by 6.21%. Lastly, the company's EPS was $0.0006, missing the average prediction of $-0.19 by -100.32%